vidutolimod
vidutolimod: sourced relationships with 1 company · 2 clinical trials tracked.
vidutolimod evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could vidutolimod → CMPI affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| CHECKMATE PHARMACEUTICALS, INC. (CMPI) anti-PD-1 refractory melanoma, first-line melanoma, advanced… | Phase 2 |
Clinical Trial Registry Records (2)
Phase 2 Platform Trial of Combination Therapies for Participants With Locally Advanced Basal Cell Carcinoma: Master Protocol With Cemiplimab Monotherapy as Comparator Arm
Primary endpoint: Objective Response Rate (ORR) by blinded independent central review (BICR) per Composite Response Criteria
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Cemiplimab in Subjects With Selected Types of Advanced or Metastatic Cancer
Primary endpoint: Objective Response Rate (ORR)
Frequently asked questions
Which companies have sourced relationships with vidutolimod?
vidutolimod has dated SEC/FDA relationship records for CHECKMATE PHARMACEUTICALS, INC..
How many clinical trials involve vidutolimod?
BioSniper tracks 2 clinical trials involving vidutolimod.